Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Summary of publications:
Publications (original articles or review articles) published in 2020 from OUS - Lymphoma biology group
7 publications found
Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology
Methods Mol Biol, 2115, 445-454
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Br J Haematol, 189 (4), 661-671
Tuning the Antigen Density Requirement for CAR T-cell Activity
Cancer Discov, 10 (5), 702-723
Cell Cycle Analysis and Relevance for Single-Cell Gating in Mass Cytometry
Cytometry A, 97 (8), 832-844
Reduced polyfunctional T cells and increased cellular activation markers in adult allergy patients reporting adverse reactions to food
BMC Immunol, 21 (1), 43
T-cell receptor therapy (TCR) against melanoma -immunotherapy for the future?
Scand J Immunol, e12927 (in press)
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Blood Adv, 4 (9), 1859-1866